Recent 8-K filings for ALBT
Highest-materiality recent filing
Avalon GloboCare merges with YOOV; YOOV had $45.7M revenue, $3.4M net income in 2024
- YOOV CY2024 unaudited revenue $45.7M, net income $3.4M; up from $28.7M rev, ($2.4M) loss in 2023.
- Post-merger, YOOV shareholders expected to own ~97.5-97.8% of combined co; Avalon shareholders ~2.2-2.5%.
-
Avalon GloboCare files pro forma financials for sale of real estate unit to Chairman for $9M
Sale of Avalon RT 9 Properties to Chairman Wenzhao Lu for $9M; excess proceeds ~$2M recorded to additional paid-in capital.
-
Avalon GloboCare receives Nasdaq notice of non-compliance with minimum bid price rule
Nasdaq notified Avalon GloboCare on April 15, 2026 of bid price deficiency per Listing Rule 5550(a)(2).
-
Avalon Globocare shareholders approve reverse stock split, note conversions, and Lu exchange
All 7 proposals passed at special meeting on March 30, 2026.
-
Avalon GloboCare corrects share count in $2.8M private placement
The amendment corrects the number of shares reported under Item 3.02 in the original March 2 filing.
-
Avalon GloboCare closes $3.25M private placement with up to $6.5M additional warrant proceeds
Issued 6,372,550 shares (or pre-funded warrants) at $0.51, plus Series A-1/A-2 warrants for 6,372,550 shares each at $0.51.
-
Avalon Globocare issues $233,910 convertible note; three directors resign, three appointed
Note principal $233,910 (incl. $26,910 OID); net proceeds $207,000; matures Feb 15, 2027.
-
Avalon GloboCare sells 100% of property subsidiary to Chairman for $9M, relieved of $5.9M mortgage
Sold 100% membership interests in Avalon RT 9 Properties, LLC to Chairman Wenzhao Lu for $9M total consideration.
-
Avalon GloboCare converts $2.6M of debentures to common stock, slashes debt
Converted $2.6M principal from June 2024 institutional note into shares; $288K repaid in cash.
-
Avalon GloboCare renews FDA registration for KetoAir; plans Q2 2026 launch via Catch-Up AI platform
FDA registration renewed for KetoAir breathalyzer (Reg. No. 3026284320) for ketogenic health management.
-
Avalon GloboCare regains Nasdaq minimum equity compliance, launches generative AI video platform
Nasdaq confirmed compliance with minimum stockholders' equity rule 5550(b); previous hearing cancelled.
-
Acquired RPM Interactive, a generative AI SaaS platform for automated short-form video, via merger with subsidiary Avalon Quantum AI.
-
Avalon GloboCare receives Nasdaq delisting notice over equity deficiency
On Nov 19, 2025, Nasdaq notified Avalon GloboCare (ALBT) it is not in compliance with Listing Rule 5550(b) due to stockholders' equity of ($3,891,270) vs required $2.5M.
-
Avalon GloboCare reveals YOOV preliminary FY2025 revenue of $59.3M, net income $3.8M
YOOV's preliminary unaudited FY2025 (year ended March 31, 2025): revenue $59.3M, net income $3.8M (206% growth).
-
Sold 121,200 shares and pre-funded warrants for 354,300 shares at $475,500; net proceeds $450,500.
-
Avalon GloboCare receives Nasdaq delisting notice for negative stockholders' equity
Stockholders' equity of ($3,891,270) as of March 31, 2025, below Nasdaq's $2.5M minimum.
-
Avalon GloboCare files S-4 for merger with YOOV; creates AIaaS company
Avalon and YOOV filed Form S-4 with SEC for proposed merger, advancing deal first announced March 7, 2025.
-
Avalon GloboCare merges with YOOV; YOOV had $45.7M revenue, $3.4M net income in 2024
YOOV CY2024 unaudited revenue $45.7M, net income $3.4M; up from $28.7M rev, ($2.4M) loss in 2023.
-
Avalon GloboCare redeems 40% stake in Laboratory Services MSO for $1.745M
Avalon Lab sells its 40% equity interest in Laboratory Services MSO, LLC back to the entity for $1,745,000 total consideration.
-
Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology
Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.
Materiality & sentiment trend
Max materiality 1.00 · Median 0.53 · Most common event other_material